BRISBANE, Calif., Jan. 6, 2023 (GLOBE NEWSWIRE) — Annexon, Inc. ANNX, a clinical-stage biopharmaceutical company developing a new class of complementary medicines for patients with classic complement-mediated autoimmune, neurodegenerative and ocular diseases, today announced that Dean “Rick” Artis, Ph.D., has been appointed Chief Scientific Officer ( CSO ), successor to Larry C. Mattheakis, Ph.D. dr Artis most recently served as CSO at Octant Bio and previously led Annexon’s efforts to discover the Company’s small molecule classical complement inhibitors, including ANX1502.

“Since our inception, we have been focused on bringing breakthrough treatments to patients with complement-mediated diseases. I’m proud of the progress we’ve made to date and want to thank Larry for his contribution and leadership that brings us to this point,” said Douglas Love, President and Chief Executive Officer of Annexon. “The next few years will be for our Company to be transformative as we continue to develop our extensive complement pipeline and multiple mid to late stage studies are underway. It is a pleasure to welcome Rick back to the Annexon team to lead our research efforts. He is an experienced CSO A leader in computational and structure-based drug design, medicinal chemistry and translational clinical development, his discovery of our first small molecule of its kind, ANX1502, was a milestone for our company and he has a proven track record that will help us continue to expand the potential of our science and work toward our mission, neuarti provide therapies to patients in need.”

As CSO of Annexon, Dr. Artis will be responsible for leading all research efforts with a particular focus on expanding small molecule research and continuing to build the Company’s robust pipeline. Prior to his final role as CSO at Octant, Dr. Artis as Senior Vice President, Chemistry at Annexon, Senior Vice President,…